Original Full Length ArticleAdiponectin receptor 1 regulates bone formation and osteoblast differentiation by GSK-3β/β-Catenin signaling in mice
Introduction
The relationship between bone and fat formation within the bone marrow microenvironment is complex and remains an area of active investigation. Clinical and experimental findings suggest that acceleration of adipogenesis in the bone marrow, known as fatty marrow, is often observed in association with the progression of osteoporosis or aging [1]. Adiponectin (ApN) and its receptors play important roles in regulating glucose and lipid metabolism [2], [3], [4]. In addition, their expressions in bone marrow-derived osteoblasts and adipocytes suggest a potential role in bone metabolism [5], [6]. Several clinical studies indicate that adiponectin is negatively associated with bone formation [7], [8]. However, adiponectin increases differentiation and mineralization of bone marrow-derived mesenchymal stem cells (MSCs) [9], [10].
ApN stimulates osteoblastogenesis and suppresses osteoclastogenesis to promote bone formation [6], [9], [10]. There are three distinct ApN actions in bone formation: (1) a direct positive endocrine action through circulatory ApN; (2) an autocrine/paracrine action; and (3) indirect endocrine effects by interacting with other signaling pathways such as insulin and bone morphogenetic protein 2 (BMP2) [6], [9], [10].
Several studies confirm the positive endocrine role of ApN in bone formation. Challa et al. [11] suggest that ApN increases chondrocyte proliferation, proteoglycan synthesis and matrix mineralization by upregulating the expression of type II collagen and runt-related transcription factor 2 and increasing the activities of alkaline phosphatase. A similar effect is observed by Oshima et al. [9] who treated C57BL/6J mice with adenoviral-derived ApN and found that ApN increased trabecular bone mass and enhanced the mineralization activity of osteoblasts (Ob), accompanied with decreased number of osteoclasts and bone resorption activity. Lee and his colleagues [12] find that circulating ApN augments gene expression of several osteogenic markers and increases Ob differentiation in mesenchymal progenitor cells. Moreover, ApN activates p38 mitogen-activated protein kinase via AdipoR1, which results in c-Jun activation and up-regulation of the target gene, cyclooxygenase-2 (COX-2). ApN also stimulates BMP2 expression in a COX2-dependent manner and therefore increases Ob differentiation [12]. An alternative action of ApN by Huang et al. [13] indicates that ApN stimulates osteoblast differentiation by an increase in BMP-2 expression with involvements of AMPK, p38 and NF-κB.
ApN also regulates bone formation in an autocrine/paracrine manner. ApN and its receptors are expressed in Ob and osteoclasts, indicating ApN and its receptor participate in bone metabolism not only through an endocrine pathway, but also locally in the bone [6], [14]. Cultures of bone marrow cells from ApN-knockout (Ad−/−) mice have significantly less osteogenesis than cultures from WT mice. Collectively, these results suggest a positive autocrine/paracrine action of ApN on bone formation.
ApN also has indirect effects on bone possibly through modulation the action of growth factor or insulin sensitivity. In the presence of insulin and BMP (but not IGF-1), ApN stimulates Ob differentiation in bone marrow cells [6]. Liu et al. [15] cultured Ob with the secretory product of adipocytes and found an inhibitory effect on Ob differentiation, which can be reversed by knockdown of AdipoR1. Other studies have produced results that do not indicate a similar effect of ApN on bone formation [16], [17].
ApN forms multi-mer complexes including trimers, hexamers and high-molecular-weight forms and various forms of ApN have distinct sensitivity for ApN receptors [3], [4]. In order to study ApN signaling specifically, we have successfully established the pAdipoR1 transgenic system and confirm the role of AdipoR1 in glucose and lipid metabolism [18]. The purpose of this study is to define the role of adiponectin receptor 1 on the differentiation of Ob using primary mesenchymal stem cells (MSCs) and preosteoblasts, and to explore mechanisms.
Section snippets
Animal experiments
pAdipoR1 transgenic mice were established by the pronuclear microinjection method of fertilized eggs from the FVB/NJNarl strain of mice as previous described [18]. Wild-type and pAdipoR1 transgenic mice were randomly assigned to six groups. Mice from both genders were analyzed using the μCT scanner at different ages (8, 32 and 56 weeks). Body weight was measured at each age. Femur were histologically examined and immunostained for osteocalcin. The measurements follow the standard nomenclature,
pAdipoR1 transgenic mice have higher bone volume and trabecular number than wild-type mice
Our pAdipoR1 mice had lower body weight at 8, 32 and 56 weeks of age in both genders (Figs. 1A and B), as previously observed [18]. Fifty-six-week old pAdipoR1 transgenic mice of both genders had higher bone mineral density than wild-type mice (Figs. 1C–D). The bone volume and trabecular number was greater in transgenic than in wild-type 8- and 56-week old female mice. The same trend was seen in male mice (Figs. 1E–H). Furthermore, trabecular thickness was significantly greater in 8-week old
Discussion
Previous studies indicate conflicting functions for ApN on bone metabolism [16], [17]. Consequently, we believe that critical downstream mechanisms have not yet been clarified. To address the critical role of AdipoR1, we used pAdipoR1 transgenic mice as an animal model to evaluate the role of AdipoR1 on bone physiology. In pAdipoR1 transgenic mice, we have confirmed the AdipoR1 expression is higher than wild type about two fold in muscle, liver, white adipose tissue and MSC [18], [21]. Our data
Acknowledgement
The study was supported in part by NSC 102-2313-B-002-026-MY3 and NSC 99-2628-B-002-067-MY3 grants from National Science Council (NSC) of Taiwan. We thank the Taiwan Mouse Clinic (NSC 102-2325-B-001-042) which is funded by the National Research Program for Biopharmaceuticals (NRPB) at the National Science Council (NSC) of Taiwan for the technical support in μCT measurement.
References (34)
- et al.
Adiponectin receptor as a key player in healthy longevity and obesity-related diseases
Cell Metab
(2013) - et al.
Adiponectin and its receptors are expressed in bone-forming cells
Bone
(2004) - et al.
Adiponectin as a novel determinant of bone mineral density and visceral fat
Bone
(2003) - et al.
Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast
Biochem Biophys Res Commun
(2005) - et al.
Effect of adiponectin on ATDC5 proliferation, differentiation and signaling pathways
Mol Cell Endocrinol
(2010) - et al.
Modulation of glucose and lipid metabolism by porcine adiponectin receptor 1-transgenic mesenchymal stromal cells in diet-induced obese mice
Cytotherapy
(2013) - et al.
Reciprocal roles of MSX2 in regulation of osteoblast and adipocyte differentiation
J Biol Chem
(2004) - et al.
Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway
Exp Cell Res
(2005) - et al.
Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism
Cell
(2010) - et al.
Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition
Cell
(2010)
Endocrine regulation of energy metabolism by the skeleton
Cell
Mechanisms of disease: is osteoporosis the obesity of bone?
Nat Clin Pract Rheumatol
Cloning of adiponectin receptors that mediate antidiabetic metabolic effects
Nature
Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases
Int J Obes
Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways
J Cell Biochem
Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus
Eur J Endocrinol
Hyperadiponectinemia enhances bone formation in mice
BMC Musculoskelet Disord
Cited by (55)
Adiponectin-mediated regulation of the adiponectin cascade in cardiovascular disease: Updates
2024, Biochemical and Biophysical Research CommunicationsThe influence of maternal levels of vitamin D and adiponectin on offspring's health
2022, Pediatrics and NeonatologyUpdate on the effects of energy metabolism in bone marrow mesenchymal stem cells differentiation
2022, Molecular MetabolismCitation Excerpt :Recently, adiponectin has been proven a critical regulator in BMSC differentiation [89]. Some in vitro studies have indicated that within the bone marrow niche, adiponectin is apt to promoteosteogenic differentiation [92–96]. Supplementation of full-length [92,96] or globular [97] adiponectin can increase the expression of the osteogenic-related genes ALP [92,96,97] and osteopontin [92,97] in C3H10T1/2 cells [92].
The adiponectin receptor agonist AdipoRon normalizes glucose metabolism and prevents obesity but not growth retardation induced by glucocorticoids in young mice
2020, Metabolism: Clinical and Experimental
- 1
These authors contributed equally to this study.